Vanguard Fiduciary Trust
KROS icon

Vanguard Fiduciary Trust’s Keros Therapeutics KROS Stock Holding History

Vanguard Fiduciary Trust’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.41M Buy
131,314
+4,012
+3% +$44.7K ﹤0.01% 2865
2026
Q1 		$1.41M Buy
+127,302
New +$1.97M ﹤0.01% 2750

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Vanguard Fiduciary Trust's KROS Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Keros Therapeutics (KROS) stake by 3.2% in Q2 2026, buying an estimated $44.7K and bringing the position to 131,314 shares worth $1.41M. The position accounts for ﹤0.01% of the portfolio, ranked #2865.

Vanguard Fiduciary Trust first reported a position in KROS in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.41M in Q1 2026. 131 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Vanguard Fiduciary Trust held 131,314 shares of Keros Therapeutics worth $1.41M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 4,012 Keros Therapeutics shares in Q2 2026, an estimated $44.7K.
  • Keros Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #2865 holding.
  • Vanguard Fiduciary Trust first reported a position in Keros Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Fiduciary Trust's Keros Therapeutics position peaked at $1.41M in Q1 2026.
  • 131 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.